-
1
-
-
77951629946
-
Capecitabine in addition to anthracyclineand taxane-based neoadjuvant treatment in patients with primary breast cancer: Phase III GeparQuattro study
-
von Minckwitz G, Rezai M, Loibl S, et al. Capecitabine in addition to anthracyclineand taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol 2010;28(12):2015-2023.
-
(2010)
J Clin Oncol
, vol.28
, Issue.12
, pp. 2015-2023
-
-
Von Minckwitz, G.1
Rezai, M.2
Loibl, S.3
-
2
-
-
38349195021
-
Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy
-
Jeruss JS, Mittendorf EA, Tucker SL, et al. Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy. J Clin Oncol 2008;26(2):246-252.
-
(2008)
J Clin Oncol
, vol.26
, Issue.2
, pp. 246-252
-
-
Jeruss, J.S.1
Mittendorf, E.A.2
Tucker, S.L.3
-
3
-
-
2942702177
-
The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trial
-
DOI 10.1200/JCO.2004.05.207
-
Thomas E, Holmes FA, Smith TL, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 2004;22(12):2294-2302. (Pubitemid 41115385)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.12
, pp. 2294-2302
-
-
Thomas, E.1
Holmes, F.A.2
Smith, T.L.3
Buzdar, A.U.4
Frye, D.K.5
Fraschini, G.6
Singletary, S.E.7
Theriault, R.L.8
McNeese, M.D.9
Ames, F.10
Walters, R.11
Hortobagyi, G.N.12
-
4
-
-
0032751112
-
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer
-
Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17(11):3412-3417. (Pubitemid 29517908)
-
(1999)
Journal of Clinical Oncology
, vol.17
, Issue.11
, pp. 3412-3417
-
-
Buzdar, A.U.1
Singletary, S.E.2
Theriault, R.L.3
Booser, D.J.4
Valero, V.5
Ibrahim, N.6
Smith, T.L.7
Asmar, L.8
Frye, D.9
Manuel, N.10
Kau, S.-W.11
McNeese, M.12
Strom, E.13
Hunt, K.14
Ames, F.15
Hortobagyi, G.N.16
-
5
-
-
0034001789
-
18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
-
Schelling M, Avril N, Nährig J, et al. Positron emission tomography using [(18)F] Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18(8):1689-1695. (Pubitemid 30220547)
-
(2000)
Journal of Clinical Oncology
, vol.18
, Issue.8
, pp. 1689-1695
-
-
Schelling, M.1
Avril, N.2
Nahrig, J.3
Kuhn, W.4
Romer, W.5
Sattler, D.6
Werner, M.7
Dose, J.8
Janicke, F.9
Graeff, H.10
Schwaiger, M.11
-
6
-
-
33947230930
-
18F]fluorodeoxyglucose positron emission tomography
-
DOI 10.1200/JCO.2006.05.7406
-
Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006;24(34):5366-5372. (Pubitemid 46623167)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.34
, pp. 5366-5372
-
-
Rousseau, C.1
Devillers, A.2
Sagan, C.3
Ferrer, L.4
Bridji, B.5
Campion, L.6
Ricaud, M.7
Bourbouloux, E.8
Doutriaux, I.9
Clouet, M.10
Berton-Rigaud, D.11
Bouriel, C.12
Delecroix, V.13
Garin, E.14
Rouquette, S.15
Resche, I.16
Kerbrat, P.17
Chatal, J.F.18
Campone, M.19
-
8
-
-
70350539566
-
18FFDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer
-
Duch J, Fuster D, Muñoz M, et al. 18FFDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009;36(10):1551-1557.
-
(2009)
Eur J Nucl Med Mol Imaging
, vol.36
, Issue.10
, pp. 1551-1557
-
-
Duch, J.1
Fuster, D.2
Muñoz, M.3
-
9
-
-
67349209897
-
The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
-
Kumar A, Kumar R, Seenu V, et al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol 2009;19(6):1347-1357.
-
(2009)
Eur Radiol
, vol.19
, Issue.6
, pp. 1347-1357
-
-
Kumar, A.1
Kumar, R.2
Seenu, V.3
-
10
-
-
77957356704
-
The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: Comparison with ultrasonography and magnetic resonance imaging
-
Choi JH, Lim HI, Lee SK, et al. The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging. J Surg Oncol 2010;102(5):392-397.
-
(2010)
J Surg Oncol
, vol.102
, Issue.5
, pp. 392-397
-
-
Choi, J.H.1
Lim, H.I.2
Lee, S.K.3
-
11
-
-
50849118098
-
Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: Prognostic value as compared with histopathology
-
Emmering J, Krak NC, Van der Hoeven JJ, et al. Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology. Ann Oncol 2008;19(9):1573-1577.
-
(2008)
Ann Oncol
, vol.19
, Issue.9
, pp. 1573-1577
-
-
Emmering, J.1
Krak, N.C.2
Van Der Hoeven, J.J.3
-
12
-
-
74649084527
-
Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy
-
Jung SY, Kim SK, Nam BH, et al. Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol 2010;17(1):247-253.
-
(2010)
Ann Surg Oncol
, vol.17
, Issue.1
, pp. 247-253
-
-
Jung, S.Y.1
Kim, S.K.2
Nam, B.H.3
-
13
-
-
18844386580
-
Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy
-
DOI 10.1007/s10549-004-5819-2
-
Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 2005;91(1):1-10. (Pubitemid 40684933)
-
(2005)
Breast Cancer Research and Treatment
, vol.91
, Issue.1
, pp. 1-10
-
-
Pickles, M.D.1
Lowry, M.2
Manton, D.J.3
Gibbs, P.4
Turnbull, L.W.5
-
14
-
-
33646148970
-
Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: Initial clinical results
-
Padhani AR, Hayes C, Assersohn L, et al. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 2006;239(2):361-374.
-
(2006)
Radiology
, vol.239
, Issue.2
, pp. 361-374
-
-
Padhani, A.R.1
Hayes, C.2
Assersohn, L.3
-
15
-
-
58149198586
-
Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer
-
Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008;14(20):6580-6589.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.20
, pp. 6580-6589
-
-
Ah-See, M.L.1
Makris, A.2
Taylor, N.J.3
-
16
-
-
33644863001
-
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
-
DOI 10.1200/JCO.2005.03.4645
-
Wedam SB, Low JA, Yang SX, et al. Anti-angiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006;24(5):769-777. (Pubitemid 46622044)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.5
, pp. 769-777
-
-
Wedam, S.B.1
Low, J.A.2
Yang, S.X.3
Chow, C.K.4
Choyke, P.5
Danforth, D.6
Hewitt, S.M.7
Berman, A.8
Steinberg, S.M.9
Liewehr, D.J.10
Plehn, J.11
Doshi, A.12
Thomasson, D.13
McCarthy, N.14
Koeppen, H.15
Sherman, M.16
Zujewski, J.17
Camphausen, K.18
Chen, H.19
Swain, S.M.20
more..
-
17
-
-
66749184675
-
Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI
-
Johansen R, Jensen LR, Rydland J, et al. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. J Magn Reson Imaging 2009;29(6):1300-1307.
-
(2009)
J Magn Reson Imaging
, vol.29
, Issue.6
, pp. 1300-1307
-
-
Johansen, R.1
Jensen, L.R.2
Rydland, J.3
-
18
-
-
0642376397
-
Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy
-
Mankoff DA, Dunnwald LK, Gralow JR, et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 2003;44(11):1806-1814. (Pubitemid 39663314)
-
(2003)
Journal of Nuclear Medicine
, vol.44
, Issue.11
, pp. 1806-1814
-
-
Mankoff, D.A.1
Dunnwald, L.K.2
Gralow, J.R.3
Ellis, G.K.4
Schubert, E.K.5
Tseng, J.6
Lawton, T.J.7
Linden, H.M.8
Livingston, R.B.9
-
19
-
-
78349273661
-
Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer
-
Partridge SC, Vanantwerp RK, Doot RK, et al. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. J Magn Reson Imaging 2010;32(5):1124-1131.
-
(2010)
J Magn Reson Imaging
, vol.32
, Issue.5
, pp. 1124-1131
-
-
Partridge, S.C.1
Vanantwerp, R.K.2
Doot, R.K.3
-
20
-
-
0032828135
-
1- weighted MRI of a diffusable tracer: Standardized quantities and symbols
-
DOI 10.1002/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S
-
Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10(3):223-232. (Pubitemid 29463104)
-
(1999)
Journal of Magnetic Resonance Imaging
, vol.10
, Issue.3
, pp. 223-232
-
-
Tofts, P.S.1
Brix, G.2
Buckley, D.L.3
Evelhoch, J.L.4
Henderson, E.5
Knopp, M.V.6
Larsson, H.B.W.7
Lee, T.-Y.8
Mayr, N.A.9
Parker, G.J.M.10
Port, R.E.11
Taylor, J.12
Weisskoff, R.M.13
-
21
-
-
77954534879
-
Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: Synopsis of Version 1.0
-
Fukukita H, Senda M, Terauchi T, et al. Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 1.0. Ann Nucl Med 2010;24(4):325-334.
-
(2010)
Ann Nucl Med
, vol.24
, Issue.4
, pp. 325-334
-
-
Fukukita, H.1
Senda, M.2
Terauchi, T.3
-
22
-
-
66149139452
-
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors
-
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(Suppl 1):122S-150S.
-
(2009)
J Nucl Med
, vol.50
, Issue.SUPPL. 1
-
-
Wahl, R.L.1
Jacene, H.2
Kasamon, Y.3
Lodge, M.A.4
-
23
-
-
6944235697
-
Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: A simulation study
-
Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45(9):1519-1527. (Pubitemid 47618506)
-
(2004)
Journal of Nuclear Medicine
, vol.45
, Issue.9
, pp. 1519-1527
-
-
Boellaard, R.1
Krak, N.C.2
Hoekstra, O.S.3
Lammertsma, A.A.4
-
24
-
-
0032757213
-
18F]- fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations
-
DOI 10.1016/S0959-8049(99)00229-4, PII S0959804999002294
-
Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35(13):1773-1782. (Pubitemid 29512308)
-
(1999)
European Journal of Cancer
, vol.35
, Issue.13
, pp. 1773-1782
-
-
Young, H.1
Baum, R.2
Cremerius, U.3
Herholz, K.4
Hoekstra, O.5
Lammertsma, A.A.6
Pruim, J.7
Price, P.8
-
25
-
-
57849117384
-
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
-
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
-
(2009)
Eur J Cancer
, vol.45
, Issue.2
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
-
26
-
-
0031975835
-
Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer
-
Honkoop AH, van Diest PJ, de Jong JS, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998;77(4):621-626. (Pubitemid 28059470)
-
(1998)
British Journal of Cancer
, vol.77
, Issue.4
, pp. 621-626
-
-
Honkoop, A.H.1
Van Diest, P.J.2
De Jong, J.S.3
Linn, S.C.4
Giaccone, G.5
Hoekman, K.6
Wagstaff, J.7
Pinedo, H.M.8
-
27
-
-
33748741191
-
Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration
-
DOI 10.1093/annonc/mdl136
-
Semple SI, Staff RT, Heys SD, et al. Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration. Ann Oncol 2006;17(9):1393-1398. (Pubitemid 44400377)
-
(2006)
Annals of Oncology
, vol.17
, Issue.9
, pp. 1393-1398
-
-
Semple, S.I.K.1
Staff, R.T.2
Heys, S.D.3
Redpath, T.W.4
Welch, A.E.5
Ahearn, T.S.6
Hutcheon, A.W.7
Gilbert, F.J.8
|